Precision-first therapies
Endpoint Health is on a mission to address urgent needs in immune-driven critical and chronic illnesses by delivering therapies that are personalized to each patient’s biology. We built Endpoint Health from the ground up to develop and commercialize therapeutics and therapy-guiding tests, to ensure that every patient receives personalized treatment that will dramatically improve their outcomes. Our vision is a world in which all patients have effective, personalized treatment, because therapies are targeted to the right patient at the right time.
Active Founders
Diego Rey, Founder/CSO
Diego is a co-founder, board member, and the Chief Scientific Officer of Endpoint Health a precision-first(TM) therapeutics company. Prior to Endpoint, Diego co-founded GeneWEAVE, a diagnostics company that develops diagnostic products for detecting infections and guiding antibiotic therapy. Started in 2010, GeneWEAVE raised $25M in venture financing and was acquired by Roche in 2015 for $425M. In between Roche and Endpoint Diego was a visiting partner at YC focused on bio companies.
Jason Springs, Founder
Leonardo Teixeira, Founder
